Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of “Moderate Buy” from Analysts

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) has received an average rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $55.00.

A number of research firms have recently weighed in on SLN. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st. Jefferies Financial Group upgraded shares of Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, June 17th. Finally, Cantor Fitzgerald started coverage on shares of Silence Therapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating for the company.

Silence Therapeutics Stock Down 7.8%

SLN stock traded down $0.77 during trading on Friday, hitting $9.09. 365,408 shares of the company’s stock traded hands, compared to its average volume of 594,265. The firm has a market capitalization of $429.41 million, a P/E ratio of -5.72 and a beta of 1.38. Silence Therapeutics has a 1 year low of $4.19 and a 1 year high of $11.06. The business has a fifty day simple moving average of $7.59 and a two-hundred day simple moving average of $6.45.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Friday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The company had revenue of $0.42 million for the quarter, compared to the consensus estimate of $1.25 million. Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. On average, equities research analysts predict that Silence Therapeutics will post -0.83 EPS for the current fiscal year.

Institutional Trading of Silence Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its position in shares of Silence Therapeutics by 18.1% in the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock worth $121,000 after purchasing an additional 1,698 shares in the last quarter. Boothbay Fund Management LLC increased its position in Silence Therapeutics by 1.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after buying an additional 2,409 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Silence Therapeutics by 6.6% during the third quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after acquiring an additional 3,935 shares in the last quarter. ADAR1 Capital Management LLC grew its position in Silence Therapeutics by 26.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock worth $144,000 after purchasing an additional 5,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Silence Therapeutics by 65.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after purchasing an additional 5,421 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.